Home
About Us
Pipeline
Investors
News & Events
Careers
| S*BIO Vision | Background | S*BIO Management | Board of Directors | Scientific Advisory Board | Corporate Values |
| Clinical Trials | R&D Programmes | Technologies & Capabilities | S*BIO’s Functional Capabilities | Publications |
| Investors | Partnerships |
| News & Press Releases | Participation in Events |
| Join Our Team | Job Openings | How to Apply |
 |
 |
|
A new scientific truth does not triumph by convincing its opponents and making them see the light, but rather because its opponents eventually die, and a new generation grows up that is familiar with it. Max Planck |
|
|
|
Clinical Trials S*BIO is currently conducting a dose-escalation Phase 1 clinical study to evaluate the safety and tolerability of SB939 in patients with either solid or hematological tumors. Patients: For more information about this study on SB939, please either call +65 67722611 or email ai_bee_ong@nuh.com.sg to get in contact with the Clinical Research Manager at the Cancer Institute@National UniversityHospital
|